



Idera Pharmaceuticals Appoints Louis Arcudi as Chief Financial Officer

November 14, 2007 1:31 PM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2007--Idera Pharmaceuticals, Inc. (AMEX: IDP), a biopharmaceutical company focused on developing therapeutics targeting Toll-like Receptors (TLR), announced today the appointment of Louis J. Arcudi III, as Chief Financial Officer. Over the past 10 years, Mr. Arcudi has served in various finance and administration capacities at Peptimmune, Inc., Genzyme Molecular Oncology Corporation and Genzyme Corporation. Mr. Arcudi will join the Company on December 3, 2007.

"Louis brings extensive financial and operational management experience to Idera," said Sudhir Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer. "We expect him to play a key role in the Company as we continue to advance our drug discovery and development programs targeted to TLRs."

Mr. Arcudi most recently served as Vice President of Finance and Administration and Treasurer for Peptimmune, Inc. and was responsible for all financial business and operations. Prior to his four years at Peptimmune, Mr. Arcudi was Senior Director of Finance and Administration at Genzyme Molecular Oncology Corporation from 2000-2003 and Director of Finance Business Planning and Operations International at Genzyme Corporation from 1998-2000. Prior to joining Genzyme, he held finance positions with increasing levels of responsibility at Cognex Corporation, Millipore Corporation and General Motors Corporation. Mr. Arcudi received a Master of Business Administration from Bryant College and a Bachelor of Science Degree in accounting and information systems from the University of Southern New Hampshire.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use as vaccine adjuvants. Idera's proprietary drug candidates are designed to modulate specific TLRs, which are a family of immune system receptors. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. Idera's most advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is currently in a Phase 2 trial in oncology and in a Phase 1/2 chemotherapy combination trial in oncology. Idera's second TLR9 agonist, IMO-2125, is currently in a Phase 1 trial for the treatment of hepatitis C virus infection. Idera is collaborating with Novartis International Pharmaceutical, Ltd. for the discovery, development, and commercialization of TLR9 agonists for the treatment of asthma and allergy indications. Idera is also collaborating with Merck & Co., Inc. for the use of Idera's TLR7, 8 and 9 agonists in combination with Merck's therapeutic and prophylactic vaccines in the areas of oncology, infectious diseases, and Alzheimer's disease. For more information, visit www.iderapharma.com.

Forward Looking Statements

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether the Company will complete enrollment of clinical trials or announce trial results in the time expected; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the results of preclinical studies will be indicative of results that may be obtained in clinical trials; whether the Company's collaborations with Novartis and Merck will be successful; whether the patents and patent applications owned or licensed by Idera will protect the Company's technology and prevent others from infringing it; whether Idera's cash resources will be sufficient to fund product development and clinical trials; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q filed on November 13, 2007, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

CONTACT: Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluethje@iderapharma.com
or
MacDougall Biomedical Communications
Chris Erdman, 508-647-0209
cerdman@macbiocom.com

SOURCE: Idera Pharmaceuticals, Inc.